ARCHIVES

Rev/Vel/Dex Response Rate High In Phase I/II Study

This article is from The Cancer Letter archive.

Vol. 31 No. 1 | January 25, 2008

Download PDF Visit The Full Archive

Related Articles

Varmus, In Letter To Institute Pasteur, Reopens Discussion Of Test Kit Royalties

July 1, 1994

Rauscher For Cancer Program

May 20, 1977

FDA Approves Bexxar For Non-Hodgkin’s Lymphoma

June 27, 2003

New Biologic Therapies Showing Promise In A Variety Of Advanced Solid Tumors

June 29, 2001

NCAB Accepts Report, Seeks Comment From Researchers, Patient Groups

May 19, 1995

Anastrozole Better Than Tamoxifen For HR+ Postmenopausal Breast Cancer, Study Finds

May 27, 2005